1. Search Result
Search Result
Results for "

lung carcinoma

" in MedChemExpress (MCE) Product Catalog:

89

Inhibitors & Agonists

4

Peptides

5

Inhibitory Antibodies

20

Natural
Products

6

Recombinant Proteins

2

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7651

    Others Cancer
    Neoanhydropodophyllol is a cyclolignan derivative, with antineoplastic activity. Neoanhydropodophyllol displays cytotoxicity against several cancer cells (leukemia, lung carcinoma and colon carcinoma) .
    Neoanhydropodophyllol
  • HY-P9978

    PD-1/PD-L1 Cancer
    Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
    Toripalimab
  • HY-149677

    Mitochondrial Metabolism Cancer
    ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP) (EC50: 1.37?μM for α-casein hydrolysis by HsClpP). ZK53 is is inactive toward bacterial ClpP proteins. ZK53 induces apoptosis in H1703, H520 and SK-MES-1 cells. ZK53 induces dysregulation of mitochondrial functions in lung squamous cell carcinoma (LUSC) cells. ZK53 inhibits tumor growth in H1703 xenograft mouse model .
    ZK53
  • HY-P99743

    Biochemical Assay Reagents Cancer
    Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .
    Mitumomab
  • HY-P2045

    Arp2/3 Complex Cancer
    RA-VII is an antitumor agent that exhibits significant activity against L1210, B-16 melanoma, Lewis lung carcinoma, Colon 38 and Ehrlich carcinoma .
    RA-VII
  • HY-19015

    AT-2153

    Calmodulin Cancer
    Probimane (AT-2153) is a potent anticancer agent. Probimane is effective against mouse tumors S37, S180, Lewis lung carcinoma, L1210 and human pulmonary adenocarcinoma heterotransplanted into nude mice .
    Probimane
  • HY-169741

    Discoidin Domain Receptor Cancer
    DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma .
    DDR1-IN-10
  • HY-148260

    Ras Cancer
    KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
    KRAS G12D inhibitor 16
  • HY-168455

    PROTACs Infection
    RNAse L RIBOTAC (compound C64) is an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. (Blue: RNA ligand (HY-168456); Black: linker (HY-130591); Pink: Rnase L ligand (HY-168457))
    RNAse L RIBOTAC
  • HY-168903

    STAT Cancer
    STAT3-IN-41 (Compound 16) is a prodrug of compound 1. STAT3-IN-41 slowly releases compound 1 inhibiting STAT3 signaling pathway. STAT3-IN-41 shows antitumor activity against lung cancer, hepatocellular carcinoma and pancreatic cancer .
    STAT3-IN-41
  • HY-12204
    PFK-015
    3 Publications Verification

    Autophagy Metabolic Disease Inflammation/Immunology Cancer
    PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) .
    PFK-015
  • HY-162721

    Others Cancer
    Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) .
    Anticancer agent 242
  • HY-N0610A
    Cinnamic acid
    1 Publications Verification

    3-Phenylacrylic acid; β-Phenylacrylic acid

    Endogenous Metabolite Cancer
    Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
    Cinnamic acid
  • HY-153863

    PROTACs MEK Raf Cancer
    MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .
    MS934
  • HY-106035

    YSV

    P-glycoprotein Cancer
    Tyroservatide (YSV) is an active, low-molecular-weight polypeptide that has been shown to have antitumor effects on hepatocellular carcinoma and lung cancer cell .
    Tyroservatide
  • HY-N10363

    Others Cancer
    Pixinol, a natural glycoside, shows cytotoxicity against the human lung carcinoma GLC4 and adenocarcinoma COLO 320 cell lines (IC50=71 µM and 43 µM, respectively) .
    Pixinol
  • HY-P99594

    ZKAB001; STI-1014; STI-A1014

    PD-1/PD-L1 Cancer
    Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
    Socazolimab
  • HY-N0610AS

    3-Phenylacrylic acid-d6; β-Phenylacrylic acid-d6

    Endogenous Metabolite Cancer
    Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
    Cinnamic acid-d6
  • HY-W342604

    NAP

    Endogenous Metabolite Neurological Disease Cancer
    N-Acetylputrescine (NAP) is an endogenous metabolite widely present in animals and plants. N-Acetylputrescine can be used as a biomarker for lung squamous cell carcinoma (SCCL) and Parkinson's disease (PD) for disease diagnosis .
    N-Acetylputrescine
  • HY-N10503

    Tyrosinase Ras Raf MAPKAPK2 (MK2) Apoptosis Cancer
    Norartocarpetin is a tyrosinase inhibitor. Norartocarpetin has strong tyrosinase inhibitory activity with an IC50 value of 0.47 μM. Norartocarpetin as an antibrowning agent can be used for the research of food systems. Norartocarpetin also has a significant anticancer activity in lung carcinoma cells (NCI-H460) with an IC50 value of 22 μM. Norartocarpetin has antiproliferative effects are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion in human lung carcinoma cells .
    Norartocarpetin
  • HY-107020

    21-Aminoepothilone B

    Apoptosis Cancer
    BMS 310705 (21-Aminoepothilone B) is an analog of Epothilone B (HY-17029), targeting to malignancies such as ovarian, renal, bladder, and lung carcinoma. BMS 310705 induces significant apoptosis via mitochondrial-mediated pathway .
    BMS 310705
  • HY-N6252
    Gypenoside XLVI
    1 Publications Verification

    Others Cancer
    Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity .
    Gypenoside XLVI
  • HY-168920

    Histone Methyltransferase Apoptosis Cancer
    NSD-IN-4 (Compound A8) is a potent and an orally active NSD3 inhibitor. NSD-IN-4 induces Apoptosis in a dose-dependent manner. NSD-IN-4 exhibits significant antitumor effects against lung squamous carcinoma .
    NSD-IN-4
  • HY-136567

    Raf Cancer
    TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay .
    TBAP-001
  • HY-169579

    Polo-like Kinase (PLK) Cancer
    PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor, with IC50 of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small cell lung carcinoma .
    PLK1-IN-11
  • HY-125443

    Others Cancer
    Lucialdehydes A is a lanostante-type triterpene aldehydes, isolated from the fruiting bodies of Ganoderma lucidum. Lucialdehydes A shows cytotoxic effects on tumor cells, including Lewis lung carcinoma (LLC), T-47D, Sarcoma 180, and Meth-A tumor cell lines .
    Lucialdehyde A
  • HY-N0610AS2

    3-Phenylacrylic acid-13C3; β-Phenylacrylic acid-13C3

    Isotope-Labeled Compounds Endogenous Metabolite Cancer
    Cinnamic acid- 13C3 (3-Phenylacrylic acid- 13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells .
    Cinnamic acid-13C3
  • HY-156033

    EGFR Apoptosis Cancer
    EGFR-IN-88 (Compound 4i) is an EGFR inhibitor (IC50: 87 nM). EGFR-IN-88 shows cytotoxicity against A549 cell with an IC50? of 3.902? μM. EGFR-IN-88 can induce cell apoptosis .
    EGFR-IN-88
  • HY-P99052
    Tislelizumab
    2 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-157231A

    PERK Cancer
    HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .
    HC-5404-Fu
  • HY-158309

    Aminotransferases (Transaminases) Cancer
    hOAT-IN-1 (compound 5) is a mechanical inhibitor of human ornithine aminotransferase (hOAT). hOAT-IN-1 as a time-dependent inhibitor can form tightly bound PLP inhibitor adduct with hOAT. hOAT-IN-1 can result IN tight occupation of the active site of hOAT. hOAT-IN-1 can be used in the study of lung cell carcinoma .
    hOAT-IN-1
  • HY-168456

    Ligands for Target Protein for PROTAC Infection
    RNA recruiter 1 is the RNA ligand of RNAse L RIBOTAC (HY-168456), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter 1 can be utilized in the synthesis of RIBOTAC .
    RNA recruiter 1
  • HY-107588
    TC-I 15
    1 Publications Verification

    Integrin Cardiovascular Disease
    TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
    TC-I 15
  • HY-116758

    di-Me-PGA1

    DNA/RNA Synthesis HIV HSV Infection Cancer
    16,16-Dimethyl prostaglandin A1 (di-Me-PGA1) is a prostaglandin analog that can inhibit DNA synthesis in Lewis lung carcinoma and B 16 amelanotic melanoma cells. 16,16-Dimethyl prostaglandin A1 also inhibits viral replication in both HSV and HIV-1 infection systems .
    16,16-Dimethyl prostaglandin A1
  • HY-168458

    Target Protein Ligand-Linker Conjugates Infection
    RNA recruiter-linker 1 is the RNA ligand-linker part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter-linker 1 can be utilized in the synthesis of RIBOTAC .
    RNA recruiter-linker 1
  • HY-168457

    SARS-CoV Others
    RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC .
    RNase L ligand 2
  • HY-119110

    MMP Cancer
    LY52 is an MMP-2 and MMP-9 inhibitor. LY52 can significantly block the proteolytic activity of gelatinases, reducing the expression of MMP-2 and MMP-9 in SKOV3 cells, thereby inhibiting cell invasion. LY52 can also suppress the pulmonary metastasis of Lewis lung carcinoma cells in mice. LY52 may be used in cancer research .
    LY52
  • HY-165245

    Transmembrane Glycoprotein Cancer
    SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
    SBI-183
  • HY-12017
    PF-04217903
    3 Publications Verification

    c-Met/HGFR Cancer
    PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .
    PF-04217903
  • HY-12017A
    PF-04217903 mesylate
    3 Publications Verification

    c-Met/HGFR Cancer
    PF-04217903 mesylate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .
    PF-04217903 mesylate
  • HY-12017B

    c-Met/HGFR Cancer
    PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .
    PF-04217903 phenolsulfonate
  • HY-159803

    6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin

    Endogenous Metabolite Cancer
    IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .
    IST-622
  • HY-N4118
    Cephaeline
    1 Publications Verification

    (-)-Cephaeline; NSC 32944 free base

    Filovirus Flavivirus Keap1-Nrf2 Ferroptosis Reactive Oxygen Species Infection Cancer
    Cephaeline ((-)-Cephaeline), a desmethyl analog of Emetine, is a phenolic alkaloid in Indian Ipecac roots isolated from the Cephaelis ipecacuanha. Cephaeline exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections. Cephaeline is an inductor of histone H3 acetylation and an inhibitor of mucoepidermoid carcinoma cancer stem cells (MEC), which promotes ferroptosis by inhibiting NRF2 to exert anti-lung cancer efficacy .
    Cephaeline
  • HY-148046
    USP15-IN-1
    1 Publications Verification

    Deubiquitinase Cancer
    USP15-IN-1 is a potent USP15 inhibitor with an IC50 value of 3.76 μM. USP15-IN-1 can be used for researching anticancer .
    USP15-IN-1
  • HY-123191

    PAI-1 Cancer
    CJ-463 is a potent and selective uPA inhibitor. CJ-463 has antitumor activity .
    CJ-463
  • HY-110088
    SCH529074
    1 Publications Verification

    MDM-2/p53 Cancer
    SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
    SCH529074
  • HY-163381

    Others Cancer
    Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .
    Antiproliferative agent-48
  • HY-132202

    PD-1/PD-L1 Apoptosis Cancer
    PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy .
    PD-1/PD-L1-IN-10
  • HY-126740

    Antibiotic Fungal Infection Cancer
    Anguinomycin A is an antibiotic that exhibits good inhibitory activity against G. boninense with an MIC value of 5 µg/disk. Anguinomycin A has antitumor activity .
    Anguinomycin A
  • HY-149841

    Akt Cancer
    AKT-IN-17 is a AKt inhibitor. AKT-IN-17 inhibits AKt in A549 cells, leading to Apoptosis. AKT-IN-17 can be used in non-small cell lung cancer study .
    AKT-IN-17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: